-DOCSTART- -X- O
Abstract -X- _ O
Lassa -X- _ O
virus -X- _ O
( -X- _ O
LASV -X- _ O
) -X- _ O
, -X- _ O
a -X- _ O
member -X- _ O
of -X- _ O
the -X- _ O
Arenaviridae -X- _ O
family -X- _ O
, -X- _ O
causes -X- _ O
a -X- _ O
viral -X- _ O
hemorrhagic -X- _ O
fever -X- _ O
endemic -X- _ O
to -X- _ O
West -X- _ O
Africa -X- _ O
, -X- _ O
where -X- _ O
as -X- _ O
many -X- _ O
as -X- _ O
300,000 -X- _ O
infections -X- _ O
occur -X- _ O
per -X- _ O
year. -X- _ O
Presently -X- _ O
, -X- _ O
there -X- _ O
are -X- _ O
no -X- _ O
FDA-approved -X- _ O
LASV-specific -X- _ O
vaccines -X- _ O
or -X- _ O
antiviral -X- _ O
agents -X- _ O
, -X- _ O
although -X- _ O
the -X- _ O
antiviral -X- _ B-Comparison
drug -X- _ I-Comparison
ribavirin -X- _ I-Comparison
has -X- _ O
shown -X- _ O
some -X- _ O
efficacy. -X- _ O
A -X- _ O
recently -X- _ O
identified -X- _ O
small-molecule -X- _ B-Intervention
inhibitor -X- _ I-Intervention
of -X- _ I-Intervention
arenavirus -X- _ I-Intervention
entry -X- _ I-Intervention
, -X- _ I-Intervention
ST-193 -X- _ I-Intervention
, -X- _ O
exhibits -X- _ O
submicromolar -X- _ O
antiviral -X- _ O
activity -X- _ O
in -X- _ O
vitro. -X- _ O
To -X- _ O
determine -X- _ O
the -X- _ O
antiviral -X- _ O
utility -X- _ O
of -X- _ O
ST-193 -X- _ B-Intervention
in -X- _ O
vivo -X- _ O
, -X- _ O
we -X- _ O
tested -X- _ O
the -X- _ O
efficacy -X- _ O
of -X- _ O
this -X- _ O
compound -X- _ O
in -X- _ O
the -X- _ O
LASV -X- _ B-Patient
guinea -X- _ I-Patient
pig -X- _ I-Patient
model. -X- _ I-Patient
Four -X- _ B-Patient
groups -X- _ I-Patient
of -X- _ I-Patient
strain -X- _ I-Patient
13 -X- _ I-Patient
guinea -X- _ I-Patient
pigs -X- _ I-Patient
were -X- _ O
administered -X- _ B-Intervention
25 -X- _ I-Intervention
or -X- _ I-Intervention
80mg -X- _ I-Intervention
/ -X- _ I-Intervention
kg -X- _ I-Intervention
ST-193 -X- _ I-Intervention
, -X- _ O
25mg -X- _ B-Comparison
/ -X- _ I-Comparison
kg -X- _ I-Comparison
of -X- _ I-Comparison
ribavirin -X- _ I-Comparison
, -X- _ I-Comparison
or -X- _ I-Comparison
the -X- _ I-Comparison
vehicle -X- _ I-Comparison
by -X- _ O
the -X- _ O
intraperitoneal -X- _ O
( -X- _ O
i.p. -X- _ O
) -X- _ O
route -X- _ O
before -X- _ O
infection -X- _ O
with -X- _ O
a -X- _ O
lethal -X- _ O
dose -X- _ O
of -X- _ O
LASV -X- _ O
, -X- _ O
strain -X- _ O
Josiah -X- _ O
, -X- _ O
and -X- _ O
continuing -X- _ O
once -X- _ O
daily -X- _ O
for -X- _ O
14 -X- _ O
days. -X- _ O
Control -X- _ B-Outcome
animals -X- _ I-Outcome
exhibited -X- _ I-Outcome
severe -X- _ I-Outcome
disease -X- _ I-Outcome
, -X- _ I-Outcome
becoming -X- _ I-Outcome
moribund -X- _ I-Outcome
between -X- _ I-Outcome
days -X- _ I-Outcome
10 -X- _ I-Outcome
and -X- _ I-Outcome
15 -X- _ I-Outcome
postinfection. -X- _ I-Outcome
ST-193-treated -X- _ I-Outcome
animals -X- _ I-Outcome
exhibited -X- _ I-Outcome
fewer -X- _ I-Outcome
signs -X- _ I-Outcome
of -X- _ I-Outcome
disease -X- _ I-Outcome
and -X- _ I-Outcome
enhanced -X- _ I-Outcome
survival -X- _ I-Outcome
when -X- _ I-Outcome
compared -X- _ I-Outcome
to -X- _ I-Outcome
the -X- _ I-Outcome
ribavirin -X- _ I-Outcome
or -X- _ I-Outcome
vehicle -X- _ I-Outcome
groups. -X- _ I-Outcome
Body -X- _ I-Outcome
temperatures -X- _ I-Outcome
in -X- _ I-Outcome
all -X- _ I-Outcome
groups -X- _ I-Outcome
were -X- _ I-Outcome
elevated -X- _ I-Outcome
by -X- _ I-Outcome
day -X- _ I-Outcome
9 -X- _ I-Outcome
, -X- _ I-Outcome
but -X- _ I-Outcome
returned -X- _ I-Outcome
to -X- _ I-Outcome
normal -X- _ I-Outcome
by -X- _ I-Outcome
day -X- _ I-Outcome
19 -X- _ I-Outcome
postinfection -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
majority -X- _ I-Outcome
of -X- _ I-Outcome
ST-193-treated -X- _ I-Outcome
animals. -X- _ I-Outcome
ST-193 -X- _ I-Outcome
treatment -X- _ I-Outcome
mediated -X- _ I-Outcome
a -X- _ I-Outcome
2â€“3-log -X- _ I-Outcome
reduction -X- _ I-Outcome
in -X- _ I-Outcome
viremia -X- _ I-Outcome
relative -X- _ I-Outcome
to -X- _ I-Outcome
vehicle-treated -X- _ I-Outcome
controls. -X- _ I-Outcome
The -X- _ I-Outcome
overall -X- _ I-Outcome
survival -X- _ I-Outcome
rate -X- _ I-Outcome
for -X- _ I-Outcome
the -X- _ I-Outcome
ST-193- -X- _ I-Outcome
treated -X- _ I-Outcome
guinea -X- _ I-Outcome
pigs -X- _ I-Outcome
was -X- _ I-Outcome
62.5 -X- _ I-Outcome
% -X- _ I-Outcome
( -X- _ I-Outcome
10 -X- _ I-Outcome
/ -X- _ I-Outcome
16 -X- _ I-Outcome
) -X- _ I-Outcome
compared -X- _ I-Outcome
with -X- _ I-Outcome
0 -X- _ I-Outcome
% -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
ribavirin -X- _ I-Outcome
( -X- _ I-Outcome
0 -X- _ I-Outcome
/ -X- _ I-Outcome
8 -X- _ I-Outcome
) -X- _ I-Outcome
and -X- _ I-Outcome
vehicle -X- _ I-Outcome
( -X- _ I-Outcome
0 -X- _ I-Outcome
/ -X- _ I-Outcome
7 -X- _ I-Outcome
) -X- _ I-Outcome
groups. -X- _ I-Outcome
These -X- _ O
data -X- _ O
suggest -X- _ O
that -X- _ O
ST-193 -X- _ B-Intervention
may -X- _ O
serve -X- _ O
as -X- _ O
an -X- _ O
improved -X- _ O
candidate -X- _ O
for -X- _ O
the -X- _ O
treatment -X- _ O
of -X- _ O
Lassa -X- _ B-Patient
fever -X- _ I-Patient
. -X- _ O

